Abstract
Therapeutic blockade of PD-1/PD-L1 signaling with monoclonal antibodies (mAbs) has shown clinical success and activity across a broad set of cancer subtypes. However, monotherapy with PD-1/PD-L1 inhibitors are only effective in a subset of patients and ongoing studies show efficacy of treatment depends on a combinatorial approach. Contrary to mAbs chimeric B-cell cancer vaccines incorporating a “promiscuous” T-cell epitope have the advantage of producing a polyclonal B-cell antibody that can potentially induce memory B- and T-cell responses, while reducing immune evasion and suppression. Here, we describe a novel PD-1 B-cell peptide epitope vaccine (amino acid 92–110; PD1-Vaxx) linked to a measles virus fusion peptide (MVF) amino acid 288–302 via a four amino acid residue (GPSL) emulsified in Montanide ISA 720VG that aims to induce the production of polyclonal antibodies that block PD-1 signaling and thus trigger anticancer effects similar to nivolumab. In preclinical studies, the PD1-Vaxx outperformed the standard anti-mouse PD-1 antibody (mAb 29 F.1A12) in a mouse model of human HER-2 expressing colon carcinoma. Furthermore, the combination of PD1-Vaxx with combo HER-2 peptide vaccine (B-Vaxx) showed enhanced inhibition of tumor growth in colon carcinoma BALB/c model challenged with CT26/HER-2 cells -. The PD-1 or combined vaccines were safe with no evidence of toxicity or autoimmunity.
Original language | English (US) |
---|---|
Article number | 1818437 |
Journal | OncoImmunology |
Volume | 9 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2020 |
Keywords
- B-cell epitopes
- CT26 carcinoma
- HER-2
- Immuno-oncology
- PD-1
- PD-L1
- nivolumab; CT26/HER-2 model
- peptide cancer vaccines
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology